prademagene zamikeracel
prademagene zamikeracel is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including ZEVASKYN. Available dosage form: cellular sheet.
Drug Details
- Generic Name
- prademagene zamikeracel
- Brand Names
- ZEVASKYN
- Application Number
- BLA125807
- Sponsor
- Abeona Therapeutics Inc.
- NDC Codes
- 1
- Dosage Forms
- CELLULAR SHEET
- Routes
- TOPICAL
- Active Ingredients
- PRADEMAGENE ZAMIKERACEL
Indications and Usage
1 INDICATIONS AND USAGE ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ( 1 )